Clinical Pharmacology, Janssen Research and Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium.
Clin Pharmacokinet. 2011 May;50(5):307-18. doi: 10.2165/11539250-000000000-00000.
It is imperative that new drugs demonstrate adequate pharmacokinetic properties, allowing an optimal safety margin and convenient dosing regimens in clinical practice, which then lead to better patient compliance. Such pharmacokinetic properties include suitable peak (maximum) plasma drug concentration (C(max)), area under the plasma concentration-time curve (AUC) and a suitable half-life (t(½)). The C(max) and t(½) following oral drug administration are functions of the oral clearance (CL/F) and apparent volume of distribution during the terminal phase by the oral route (V(z)/F), each of which may be predicted and combined to estimate C(max) and t(½). Allometric scaling is a widely used methodology in the pharmaceutical industry to predict human pharmacokinetic parameters such as clearance and volume of distribution. In our previous published work, we have evaluated the use of allometry for prediction of CL/F and AUC. In this paper we describe the evaluation of different allometric scaling approaches for the prediction of C(max), V(z)/F and t(½) after oral drug administration in man.
Twenty-nine compounds developed at Janssen Research and Development (a division of Janssen Pharmaceutica NV), covering a wide range of physicochemical and pharmacokinetic properties, were selected. The C(max) following oral dosing of a compound was predicted using (i) simple allometry alone; (ii) simple allometry along with correction factors such as plasma protein binding (PPB), maximum life-span potential or brain weight (reverse rule of exponents, unbound C(max) approach); and (iii) an indirect approach using allometrically predicted CL/F and V(z)/F and absorption rate constant (k(a)). The k(a) was estimated from (i) in vivo pharmacokinetic experiments in preclinical species; and (ii) predicted effective permeability in man (P(eff)), using a Caco-2 permeability assay. The V(z)/F was predicted using allometric scaling with or without PPB correction. The t(½) was estimated from the allometrically predicted parameters CL/F and V(z)/F. Predictions were deemed adequate when errors were within a 2-fold range.
C(max) and t(½) could be predicted within a 2-fold error range for 59% and 66% of the tested compounds, respectively, using allometrically predicted CL/F and V(z)/F. The best predictions for C(max) were obtained when k(a) values were calculated from the Caco-2 permeability assay. The V(z)/F was predicted within a 2-fold error range for 72% of compounds when PPB correction was applied as the correction factor for scaling.
We conclude that (i) C(max) and t(½) are best predicted by indirect scaling approaches (using allometrically predicted CL/F and V(z)/F and accounting for k(a) derived from permeability assay); and (ii) the PPB is an important correction factor for the prediction of V(z)/F by using allometric scaling. Furthermore, additional work is warranted to understand the mechanisms governing the processes underlying determination of C(max) so that the empirical approaches can be fine-tuned further.
新药物必须具有足够的药代动力学特性,以便在临床实践中为患者提供理想的安全边际和方便的给药方案,从而提高患者的依从性。这些药代动力学特性包括适宜的峰(最大)血浆药物浓度(Cmax)、血浆浓度-时间曲线下面积(AUC)和适宜的半衰期(t1/2)。口服药物后 Cmax 和 t1/2 是口服清除率(CL/F)和口服途径末端相表观分布容积(Vz/F)的函数,可通过预测这些参数并将其结合起来估算 Cmax 和 t1/2。 体表面积标度法是制药行业中广泛用于预测人体药代动力学参数(如清除率和分布容积)的方法。在我们之前发表的工作中,我们评估了使用体表面积标度法预测 CL/F 和 AUC。在本文中,我们描述了不同的体表面积标度法在预测人体口服药物后 Cmax、Vz/F 和 t1/2 的应用。
选择了 29 种由杨森研发(杨森制药有限公司的一个部门)开发的化合物,涵盖了广泛的理化和药代动力学特性。使用以下方法预测化合物口服给药后的 Cmax:(i)单独使用简单的体表面积标度法;(ii)使用体表面积标度法,同时校正血浆蛋白结合率(PPB)、最大寿命潜能或脑重量等校正因子(反指数法则,无蛋白结合 Cmax 法);(iii)使用间接方法,通过预测的 CL/F 和 Vz/F 以及吸收速率常数(ka)。ka 通过以下方法从体内药代动力学实验(在临床前物种中)和在人(使用 Caco-2 渗透率测定)中预测的有效渗透率(Peff)进行估算。Vz/F 使用有或无 PPB 校正的体表面积标度法进行预测。t1/2 通过预测的体表面积标度参数 CL/F 和 Vz/F 进行估算。当误差在 2 倍范围内时,可认为预测是准确的。
使用预测的 CL/F 和 Vz/F 进行体表面积标度,可以在 2 倍误差范围内准确预测 Cmax 和 t1/2,分别为 59%和 66%的测试化合物。ka 值通过 Caco-2 渗透率测定计算时,Cmax 的预测效果最佳。应用 PPB 校正作为标度的校正因子时,Vz/F 可在 72%的化合物中预测到 2 倍误差范围内。
我们得出以下结论:(i)Cmax 和 t1/2 最好通过间接标度方法(使用预测的 CL/F 和 Vz/F,并考虑从渗透率测定中得出的 ka 值)进行预测;(ii)PPB 是预测 Vz/F 时的重要校正因子,可通过体表面积标度法进行校正。此外,需要进一步研究来理解决定 Cmax 的相关过程的机制,以便进一步优化经验方法。